MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 4, 2006; DOI: 10.1124/mol.106.023762


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.023762v1
70/2/656    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jakubik, J.
Right arrow Articles by Dolezal, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jakubik, J.
Right arrow Articles by Dolezal, V.


Received for publication February 24, 2006.
Revised May 4, 2006.
Accepted for publication May 4, 2006.

Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M1 and M2 muscarinic acetylcholine receptors

Jan Jakubik 1*, Esam E. El-Fakahany 2, Vladimir Dolezal 1

1 Inst. Physiology, CAS 2 University of Minnesota Medical School

* Address correspondence to: E-mail: jakubik{at}biomed.cas.cz

Abstract

Xanomeline is a functionally selective M1/M4 muscarinic acetylcholine receptor agonist that nevertheless binds with high affinity to all five subtypes of muscarinic receptors. A novel mode of interaction of this ligand with the muscarinic M1 receptors characterized by persistent binding and receptor activation after extensive washout has been previously shown. In the present study, using human M1 and M2 receptors expressed in Chinese hamster ovary cells and [3H]-N-methylscopolamine as a tracer, we show that persistent binding of xanomeline also occurs at the M2 receptor with similar affinity as at the M1 receptor (KI = 294 and 296 nM, respectively). However, kinetics of formation of xanomeline wash-resistant binding to M2 receptors were markedly slower than to M1 receptors. Xanomeline was a potent fast-acting full agonist in stimulating guanosine-5'-{gamma}[35S]thiotrisphosphate binding at M1 receptors while at M2 receptors it behaved as a potent partial agonist (40% of carbachol maximal response) only upon preincubation for one hour Development of xanomeline agonistic effects at the M2 receptor was slower than its ability to attenuate carbachol responses. We also demonstrate that xanomeline discriminates better between G-protein subtypes at M1 than at M2 receptors. Our data support the notion that xanomeline interacts with multiple sites on the muscarinic receptor, resulting in divergent conformations that exhibit differential effects on ligand binding and receptor activation. These conformations are both time and concentration dependent, and vary between the M1 and the M2 receptor.


Key words: Muscarinic cholinergic, Receptor binding studies


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
K. C. De Lorme, M. K.O. Grant, M. J. Noetzel, S. B. Polson, and E. E. El-Fakahany
Long-Term Changes in the Muscarinic M1 Receptor Induced by Instantaneous Formation of Wash-Resistant Xanomeline-Receptor Complex
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 868 - 876.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Machova, J. Jakubik, E. E. El-Fakahany, and V. Dolezal
Wash-Resistantly Bound Xanomeline Inhibits Acetylcholine Release by Persistent Activation of Presynaptic M2 and M4 Muscarinic Receptors in Rat Brain
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 316 - 323.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Michal, E. E. El-Fakahany, and V. Dolezal
Muscarinic M2 Receptors Directly Activate Gq/11 and Gs G-Proteins
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 607 - 614.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics